Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2005-03-22
2005-03-22
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C534S014000, C534S010000, C424S001110
Reexamination Certificate
active
06869590
ABSTRACT:
Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
REFERENCES:
patent: 4577042 (1986-03-01), Collins et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4752141 (1988-06-01), Sun et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 4986671 (1991-01-01), Sun et al.
patent: 5053053 (1991-10-01), De Labbey et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5275594 (1994-01-01), Baker et al.
patent: 5310535 (1994-05-01), Kruper, Jr. et al.
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5428156 (1995-06-01), Mease et al.
patent: 5739323 (1998-04-01), Kruper, Jr. et al.
patent: 5744120 (1998-04-01), Edwards et al.
patent: 5756065 (1998-05-01), Wilson et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5879659 (1999-03-01), Edwards et al.
patent: 5958374 (1999-09-01), Meares et al.
patent: 6010679 (2000-01-01), Edwards et al.
patent: 3551993 (1993-09-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 565 930 (1993-10-01), None
patent: WO 8705030 (1987-08-01), None
patent: WO 8901476 (1989-02-01), None
patent: WO 9012050 (1990-10-01), None
patent: WO 9114458 (1991-10-01), None
patent: WO 9306868 (1993-04-01), None
patent: WO 9526206 (1995-10-01), None
patent: WO 9732862 (1997-09-01), None
patent: WO 9811475 (1998-03-01), None
patent: WO 9853858 (1998-12-01), None
patent: WO 9907382 (1999-02-01), None
patent: WO 9967284 (1999-12-01), None
patent: WO 0003704 (2000-01-01), None
patent: WO 0006147 (2000-02-01), None
Agatston, A.S., et al., “Quantification of coronary artery calcium using ultrafast computed tomography,”J. Am. Coll. Cardiol., Mar. 15, 1990, 15(4), 827-832.
Alderman, E.L., et al., “Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the coronary artery surgery study,”J. Am. Coll. Cardiol., Oct. 1993, 22(4), 1141-1154.
Ambrose, J.A., et al., “Angiographic progression of coronary artery disease and the development of myocardial infarction,”J. Am. Coll. Cardiol., Jul. 1988, 12(1). 56-62.
Ambrose, J.A., “Angiographic correlations of advanced coronary lesions in acute coronary syndromes,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 105-122.
Baumgartner, H.-R., Eine neue methode zur erzeugung von thrombin durch gezielte Überdehnung der gefaβwand,Gesamte Exp. Med., 1963, 137, 227-247 (Summary in English on p. 243).
Becker, C.R., et al., “Visualization and quantification of coronary calcifications with electron beam and spiral computed tomography,”Eur. Radiol., 2000, 10, 629-635.
Bhorade, R., et al., “Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat dervied membrane translocation peptide,”Bioconjugate Chem., May/Jun. 2000, 11(3), 301-305.
Brechbiel, M.W., et al., “Backbone-substituted DTPA ligands for90Y radioimmunotherapy,”Bioconjugate Chem., 1991, 2, 187-194.
Brechbiel, M.W., et al., “Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies,”Inorg. Chem., 1986, 25, 2772-2781.
Brundage, B.H., et al., “the calcium story and electron beam computed tomography,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster, V. (Ed.),Futura Publishing Co., Inc., 1996, 417-427.
Budoff, M.J., et al., “Rates of progression of coronary calcium by electron beam tomography,”Am. J. Cardiol., Jul. 1, 2000, 86, 8-11.
Carrington, C., could coronary calcium screening prevent this?Diagnostic Imaging, Apr. 2000, 48-53.
Delbeke, D., “Oncological applications of FDG PET imaging,”J. Nucl. Med., Oct. 1999, 40(10), 1706-1715.
Dinsmore, R.E., et al., “Imaging techniques in carotid and peripheral vascular disease,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster (Ed.),Futura Publishing Co., Inc., 1996, 277-289.
Doherty, T.M., et al., “Coronary calcium: the good, the bad, and the uncertain,”Am. Heart J., May 1999, 137(5), 806-814.
Doyle, M., et al., “Magnetic resonance coronary artery imaging,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster (Ed.),Futura Publishing Co., Inc., 1996, 313-332.
Elmaleh, D.R., et al., “Rapid noninvasivedetection of experimental atherosclerotic lesions with novel99mTc-labeled diadenosine tetraphosphates,”Proc. Natl. Acad. Sci. USA, Jan. 1998, 95, 691-695.
Erbel, R., et al., “Electron-beam computed tomography for detection of early signs of coronary arteriosclerosis,”Eur. Heart J., 2000, 21, 720-732.
Farb, A., et al., “Sudden coronary death,”Circulation, Oct. 1, 1995, 92(7), 1701-1709.
Fuster, V., et al., “The pathogenesis of coronary artery disease and the acute coronary syndromes,”N. Engl. J. Med., Jan. 23, 1992, 326(4), 242-250.
Galis, Z.S., et al., “Macrophage foam cells from experimental atheroma constitutively prduce matrix-degrading proteinases,”Proc. Acad. Sci. USA, Jan. 1995, 92, 402-406.
Glover, G.H., et al., “Research directions in MR imaging,”Radiology, May 1998, 207(2), 289-295.
Goldstein, J.L., et al., “Receptor-mediated endocytosis of low-density lipoprotein in cultered cells,”Methods Enzymol., 1983, 98, 241-261.
Goldstein, J.L., et al., “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition,”Proc. Natl. Acad. Sci. USA, Jan. 1979, 76(1), 333-337.
Goyen, M., et al., “MR-angiography: the role of contrast agents,”Eur. J. Radiol., 2000, 34, 247-256.
Grist, T.M., et al., “Nuclear magnetic resonance imaging as applied to carotid and peripheral atherosclerotic vascular disease,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster (Ed.),Futura Publishing Co., Inc., 1996, 333-362.
Janowitz, W.R., et al., “Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women,”Am. J. Cardiol., Aug. 1, 1993, 72(3), 247-254.
Kaski, J.C., et al., “Rapid angiographic progression of coronary artery disease in patients with angina pectoris,”Circulation, Oct. 15, 1995, 92(8), 2058-2065.
Knopp, M.V., et al., “Contrast agents for MRA: future directions,”J. Magn. Reson. Imaging, 1999, 10, 314-316.
Kohler, T.R., “Imaging of carotid artery lesions: a surgeon's view,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, V. Fuster (Ed.),Futura Publishing Co., Inc., 1996, 205-223.
Ku, D.N., et al., “Pulsatile flow and atherosclerosis in the human carotid bifurcation,”Atheriosclerosis, May/Jun. 1985, 5(3), 293-302.
Lewin, M., et al., “Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells,”Nat. Biotechnol., Apr. 2000, 18, 410-414.
Lin, Y.-Z., et al., “Inhibition of nuclear translocation of transcription factor NF-←B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence,”J. Biol. Chem., Jun. 16, 1995, 270(24), 14255-14258.
Little, W.C., et al., “Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?,”Circulation, 1988, 78,
Edwards David Scott
Liu Shuang
Bristol-Myers Squibb Pharma Company
Jones Dameron L.
Volles Warren K.
Woodcock & Washburn LLP
LandOfFree
Labeled macrophage scavenger receptor antagonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Labeled macrophage scavenger receptor antagonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Labeled macrophage scavenger receptor antagonists for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368117